The Swiss pharmaceutical development company MetrioPharm AG, which specialises in drugs for chronic inflammatory diseases, has appointed Thomas Christély as its new chief executive, effective 1 October. He was most recently managing director and chief financial officer at MYR Pharmaceuticals GmbH. In this role, he was responsible for the company’s sale to Gilead Sciences Inc in March.
Mr Christély will focus on business development and financing at MetrioPharm, and takes over these duties from the company’s co-founder and co-owner Wolfgang Brysch. Dr Brysch will continue as chief scientific officer and chief medical officer.
MetrioPharm announced the appointment on 19 August 2021.
Copyright 2021 Evernow Publishing Ltd